TegMine Therapeutics has announced a collaboration with Boehringer Ingelheim to advance a new two-factor antibody system, aimed at developing antibody-drug conjugates (ADCs) for cancer treatment.
The partnership will focus on an initial programme targeting a clinically validated antigen, with the possibility of expanding to a further two cancer targets.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataTegMine will leverage its TegMiner platform, which identifies new, tumour-specific glycan epitopes that traditional methods may overlook.
The two-factor antibody system is designed to enhance therapeutic precision by requiring dual glycan and protein recognition.
It aims to improve specificity and efficacy while minimising on-target, off-tumour toxicity.
TegMine CEO Jeff Bernstein stated: “At TegMine, we are exploiting the unique biology of tumour-associated glycans, molecular signatures that are highly prevalent in aggressive solid tumours yet largely absent in healthy tissues.
“This collaboration endorses our approach, and specifically our two-factor antibody system, which unlocks specific tumour-associated antigens and targets that were previously inaccessible with other technologies.
“We are excited to translate this approach into potentially meaningful therapies for patients alongside a world-class partner in Boehringer Ingelheim.”
TegMine will be eligible for an upfront payment and research funding for each target, along with a target option fee for any additional selected targets.
The company will also earn clinical, preclinical, regulatory and commercial milestone payments, along with royalties on net sales from any products developed through this collaboration.
Boehringer Ingelheim will hold global development and commercial rights for all targets generated during the partnership.
In August 2025, Boehringer Ingelheim signed a contract with AnGes to develop and manufacture an investigational therapy for peripheral arterial disease.
The company’s BioXcellence division will serve as a contract development and manufacturing organisation for AnGes.
BioXcellence will focus on the production of the active pharmaceutical ingredient for the hepatocyte growth factor gene therapy product.
ADC content on Pharmaceutical Technology (Or Clinical Trials Arena) is supported by Syngene. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
